Literature DB >> 31077056

Pathological findings of progressive renal involvement in a patient with TAFRO syndrome.

Hirotaka Saito1, Kenichi Tanaka2, Momoko Fujiwara1, Tsuyoshi Iwasaki1, Tokutaro Numata1, Akira Oda1, Makoto Kanno1, Mizuko Tanaka3, Masaaki Eiro4, Mamoru Satoh4, Junichiro James Kazama1.   

Abstract

TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) is thought of as an atypical type of idiopathic multicentric Castleman's disease. Interleukin-6, vascular endothelial growth factor (VEGF), and other cytokines are considered etiological factors. A 45-year-old woman was admitted to hospital with unknown fever and abdominal pain. She had thrombocytopenia, anasarca, proteinuria/hematuria, and slight hepatosplenomegaly. Based on her clinical course and laboratory data, she was diagnosed as having TAFRO syndrome. Kidney biopsy showed a membranoproliferative glomerulonephritis (MPGN)-like lesion containing lobulations of glomeruli, endothelial cell swelling, double contours of the glomerular basement membrane, and mesangiolysis. She was treated with methylprednisolone pulse (500 mg/day) and oral prednisolone (60 mg/day) therapy. The pleural effusion and ascites disappeared, and renal function normalized. Cyclosporine was added to prevent relapse. She went home, with no relapse 8 months after hospitalization. MPGN-like lesions were found frequently in patients with TAFRO syndrome in recent reports. However, there are few reports of pathologically confirmed cases of progressive renal involvement in TAFRO syndrome. The relationship between VEGF expression in renal tissue and the pathogenesis of renal injury in TAFRO syndrome was investigated in the present case.

Entities:  

Keywords:  Kidney biopsy; TAFRO syndrome; Thrombotic microangiopathy; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2019        PMID: 31077056      PMCID: PMC6820645          DOI: 10.1007/s13730-019-00400-9

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  18 in total

1.  Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.

Authors:  Yasufumi Masaki; Hiroshi Kawabata; Kazue Takai; Masaru Kojima; Norifumi Tsukamoto; Yasuhito Ishigaki; Nozomu Kurose; Makoto Ide; Jun Murakami; Kenji Nara; Hiroshi Yamamoto; Yoko Ozawa; Hidekazu Takahashi; Katsuhiro Miura; Tsutomu Miyauchi; Shinichirou Yoshida; Akihito Momoi; Nobuyasu Awano; Soichiro Ikushima; Yasunori Ohta; Natsue Furuta; Shino Fujimoto; Haruka Kawanami; Tomoyuki Sakai; Takafumi Kawanami; Yoshimasa Fujita; Toshihiro Fukushima; Shigeo Nakamura; Tomohiro Kinoshita; Sadao Aoki
Journal:  Int J Hematol       Date:  2016-03-18       Impact factor: 2.490

2.  Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids.

Authors:  Shiho Fujiwara; Hiromi Mochinaga; Hirotomo Nakata; Koichi Ohshima; Masanori Matsumoto; Mitsuhiro Uchiba; Yoshiki Mikami; Hiroyuki Hata; Yutaka Okuno; Hiroaki Mitsuya; Kisato Nosaka
Journal:  Int J Hematol       Date:  2016-03-15       Impact factor: 2.490

3.  Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy.

Authors:  S Suga; Y G Kim; A Joly; E Puchacz; D H Kang; J A Jefferson; J A Abraham; J Hughes; R J Johnson; G F Schreiner
Journal:  Kidney Int       Date:  2001-10       Impact factor: 10.612

Review 4.  The role of vascular endothelial growth factor (VEGF) in renal pathophysiology.

Authors:  Bieke F Schrijvers; Allan Flyvbjerg; An S De Vriese
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

5.  VEGF inhibition and renal thrombotic microangiopathy.

Authors:  Vera Eremina; J Ashley Jefferson; Jolanta Kowalewska; Howard Hochster; Mark Haas; Joseph Weisstuch; Catherine Richardson; Jeffrey B Kopp; M Golam Kabir; Peter H Backx; Hans-Peter Gerber; Napoleone Ferrara; Laura Barisoni; Charles E Alpers; Susan E Quaggin
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

Review 6.  TAFRO syndrome: 2 cases and review of the literature.

Authors:  Mikako Kawashima; Taro Usui; Hideyuki Okada; Ichiro Mori; Masahiro Yamauchi; Takahide Ikeda; Kazuo Kajita; Yusuke Kito; Tatsuhiko Miyazaki; Kei Fujioka; Tatsuo Ishizuka; Hiroyuki Morita
Journal:  Mod Rheumatol       Date:  2015-07-20       Impact factor: 3.023

7.  Diffuse Large B-cell Lymphoma during Corticosteroid Therapy for TAFRO Syndrome.

Authors:  Eiko Ohya; Minoru Mizutani; Haruna Sakaguchi; Takao Sekine
Journal:  Intern Med       Date:  2016-10-01       Impact factor: 1.271

Review 8.  Successful Treatment of TAFRO Syndrome with Tocilizumab, Prednisone, and Cyclophosphamide.

Authors:  Taku Kikuchi; Takayuki Shimizu; Takaaki Toyama; Ryohei Abe; Shinichiro Okamoto
Journal:  Intern Med       Date:  2017-08-01       Impact factor: 1.271

Review 9.  Clinicopathological features of progressive renal involvement in TAFRO syndrome: A case report and literature review.

Authors:  Mari Tanaka; Hiraku Tsujimoto; Kojiro Yamamoto; Saeko Shimoda; Kazumasa Oka; Hiroya Takeoka
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

10.  Membranoproliferative glomerulonephritis-like findings for TAFRO syndrome, associated with an anterior mediastinal tumor: A case report.

Authors:  Yoshitaka Furuto; Hirotsugu Hashimoto; Hajime Horiuti; Yuko Shibuya
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

View more
  1 in total

1.  Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology.

Authors:  Sylvain Raoul Simeni Njonnou; Justine Deuson; Claire Royer-Chardon; Frédéric Alain Vandergheynst; Virginie De Wilde
Journal:  BMJ Case Rep       Date:  2020-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.